Effect of empagliflozin on all-cause hospitalization in EMPA-KIDNEY

被引：0
|
作者：
Uster, Anastasia [1 ]
Desai, Nihar [2 ]
Navaneethan, Sankar [3 ]
Pfarr, Egon [1 ]
Mazo, Anna Rita [1 ]
机构：
[1] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[2] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA
[3] Baylor Coll Med, Nephrol Sect, Dept Med, Selzman Inst Kidney Hlth, Houston, TX USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2024年 / 153卷
关键词：
D O I：
10.1016/j.metabol.2024.155857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0047
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial
    Preiss, David
    Herrington, William
    Haynes, Richard
    CIRCULATION, 2022, 146 (25) : E577 - E577
  • [2] EFFECTS OF EMPAGLIFLOZIN ON FLUID OVERLOAD IN CHRONIC KIDNEY DISEASE: AN EMPA-KIDNEY BIOIMPEDANCE SUBSTUDY
    Mayne, Kaitlin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I49 - I50
  • [3] Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Fitchett, David
    Anker, Stefan D.
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    Johansen, Odd Erik
    Jamal, Waheed
    Hantel, Stefan
    Lund, Soren S.
    INTERNIST, 2021, 62 (SUPPL 2): : 150 - 151
  • [4] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial
    Staplin, Natalie
    Haynes, Richard
    Judge, Parminder K.
    Wanner, Christoph
    Green, Jennifer B.
    Emberson, Jonathan R.
    Preiss, David
    Mayne, Kaitlin J.
    Ng, Sarah Y. A.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Petrini, Michaela
    Seide, Svenja
    Landray, Martin J.
    Baigent, Colin
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 39 - 50
  • [5] Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY
    Nangaku, Masaomi
    Herrington, William G.
    Goto, Shinya
    Maruyama, Shoichi
    Kashihara, Naoki
    Ueki, Kohjiro
    Wada, Jun
    Watada, Hirotaka
    Nakashima, Eitaro
    Lee, Ryonfa
    Massey, Dan
    Mayne, Kaitlin J.
    Tomita, Aiko
    Haynes, Richard
    Hauske, Sibylle J.
    Kadowaki, Takashi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (06) : 588 - 595
  • [6] Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
    Judge, Parminder K.
    Staplin, Natalie
    Mayne, Kaitlin J.
    Wanner, Christoph
    Green, Jennifer B.
    Hauske, Sibylle J.
    Emberson, Jonathan R.
    Preiss, David
    Ng, Sarah Y. A.
    Roddick, Alistair J.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen Jiun
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Massey, Dan
    Landray, Martin J.
    Baigent, Colin
    Haynes, Richard
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 51 - 60
  • [7] Empagliflozin reduces the total burden of all-cause hospitalisations (ACH) and mortality in EMPA-REG OUTCOME
    Inzucchi, S. E.
    Zinman, B.
    Wanner, C.
    Fitchett, D.
    Anker, S. D.
    Pocock, S.
    Kaspers, S.
    George, J. T.
    Johansen, O. E.
    Jamal, W.
    Hantel, S.
    Lund, S. S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S271 - S271
  • [8] The impact of multimorbidity on the effects of empagliflozin in chronic kidney disease (CKD): exploratory analyses from the EMPA-KIDNEY trial
    Mayne, Kaitlin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I112 - I114
  • [9] Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Fitchett, David H.
    Anker, Stefan
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    Johansen, Odd Erik
    Jamal, Waheed
    Hantel, Stefan
    Lund, Soren S.
    DIABETES, 2020, 69
  • [10] All-Cause Hospitalization Among Live Kidney Donors After Nephrectomy
    Chang, A.
    Phung, A.
    Mehta, S.
    Massie, I.
    Zeiser, L. B.
    Alejo, J.
    Warren, D. S.
    Levan, M. L.
    Sidoti, C.
    Massie, A. B.
    Segev, D. L.
    King, E.
    Muzaale, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S567 - S568
12345